Fracture recurrence in hip fracture with menopausal hormone therapy versus risedronate: a clinical trial.
Climacteric
; 24(4): 408-414, 2021 08.
Article
in En
| MEDLINE
| ID: mdl-34240673
ABSTRACT
OBJECTIVES:
An open-label, randomized trial was conducted to examine the effects of risedronate versus menopausal hormone therapy (MHT) in postmenopausal women with recent hip fracture.METHODS:
Among 1165 eligible women, 281 were recruited and randomly assigned to receive oral risedronate (35 mg/week) or percutaneous estradiol gel (1.5 mg/day) plus oral micronized progesterone (100 mg/day) for 4 years. The primary end point was recurrent fracture and the secondary end points were mortality and bone mineral density (BMD).RESULTS:
Kaplan-Meier analyses showed no significant differences in fracture recurrence and mortality between the two groups. The incidence of any new fracture per 100 person-years (PY) was 8.63 in the risedronate group and 12.86 in the MHT group (p = 0.180); that of clinical fracture was 4.75 and 6.99, respectively (p = 0.265); and that of asymptomatic vertebral fracture was 4.87 and 5.58, respectively (p = 0.764). The respective incidence of death per 100 PY was 3.58 and 4.40 (p = 0.503). BMD increased comparably at the lumbar spine in both groups. BMD at the total hip did not change in the risedronate group, but increased significantly by 2.8% in the MHT group.CONCLUSIONS:
MHT might not differ from risedronate in the prevention of secondary fractures and death among postmenopausal women with recent hip fracture.Key words
Full text:
1
Database:
MEDLINE
Main subject:
Menopause
/
Hormone Replacement Therapy
/
Risedronic Acid
/
Hip Fractures
Type of study:
Clinical_trials
Limits:
Humans
Language:
En
Journal:
Climacteric
Journal subject:
GINECOLOGIA
Year:
2021
Type:
Article